ArticleInternational journal of ophthalmology2023
0.05% atropine on control of myopia progression in Chinese school children: a randomized 3-year clinical trial.
Article in International journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Biological mechanisms of atropine in myopia control (Review).Molecular medicine reports · 2026Pooled it
- The effectiveness of atropine 0.05% eye drops versus placebo on controlling myopia progression among school children in randomized controlled trials: a systematic review and meta analysis.BMC ophthalmology · 2026Pooled it
- Efficacy of interventions for myopia control in children: A systematic review with network meta-analyses.Acta ophthalmologica · 2025Pooled it
- A systematic review of the study design and statistical practices in randomized controlled trials on myopia treatment (2019-2023).BMC ophthalmology · 2025Pooled it
- Interventions for myopia control in children: a living systematic review and network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- Exploratory multivariate adaptive regression splines modeling of myopic progression in children receiving atropine.Journal of the Chinese Medical Association : JCMA · 2026Article
- Relationship of Atropine in Controlling Myopia Progression Among Pediatric Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Effect of orthokeratology lens wear on axial length elongation in myopic children.Frontiers in medicine · 2026Article
- Atropine Eye Drops in Childhood Myopia Control: A Review.International journal of medical sciences · 2026Review
- IMI-Interventions for Controlling Myopia Onset and Progression 2025.Investigative ophthalmology & visual science · 2025Review
- Interpretation of expert consensus on the application of low-concentration atropine eye drops in the prevention and control of myopia in children and adolescents.Pediatric investigation · 2025Article
- Comparison of Myopic Progression and Quality of Life Wearing Either DIMs Lenses or Single-Vision Myopia Correcting Spectacles.Journal of ophthalmology · 2025Article
- Myopia Control: Are We Ready for an Evidence Based Approach?Ophthalmology and therapy · 2024Review
- Retardation of myopia by atropine regimes.International journal of ophthalmology · 2024Review
- Effectiveness of various atropine concentrations in myopia control for Asian children: a network meta-analysis.Frontiers in pharmacology · 2024Article
- Repeated Low-Level Red-Light Therapy for Controlling Onset and Progression of Myopia-a Review.International journal of medical sciences · 2023Review
- Impact of atropine use for myopia control on intraocular pressure in children: A comprehensive review including postpupil dilation intraocular pressure changes.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the effect of 0.05% atropine on the control of myopia for 2y (phase I) and on spherical equivalent refraction (SER) progression for 1y (phase II) after its withdrawal in Chinese myopic children.
methodsTotally 142 children with myopia were randomly assigned to the 0.05% atropine group or to the placebo group. In phase I, children received 1 treatment for each eye daily. In phase II, the patients received no treatment. Axial length (AL), SER, intraocular pressure (IOP) and atropine-related side effects were assessed at 6 months' intervals.
resultsDuring phase I, the mean change of SER was -0.46±0.30 D in the atropine group, compared to -1.72±1.12 D in the placebo group (
conclusionThe use of 0.05% atropine for two consecutive years may effectively control elongation of AL and thus progression of myopia, without significant SER progression 1y after atropine withdrawal. Therefore, treatment with 0.05% atropine daily for 2y is effective and safe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.